Market Outlook
Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed antibiotics, none were specifically developed for CROs. The recent launch of Merck & Co.’s Avycaz/Zaviceftaaddresses some of the unmet need in this area, but the majority of current treatments are combinations of generically available antibiotics, which have significant sideeffects and may extend the length of hospital stay. Thus, a high unmet need exists for the treatment of infections caused by CROs, witha significant commercial opportunity for novel agents.
Questions Answered
Product Description
Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, and Germany.
Primary research: Survey of 62 U.S. and 35 European ID specialists fielded in March 2018.
Key companies: Achaogen, Allergan, Merck & Co., Melinta Therapeutics, Pfizer, Polyphor, Shionogi, and Tetraphase.
Key drugs: Avycaz/Zavicefta, cefiderocol, eravacycline, imipenem/cilastatin, colistin, imipenem/cilastatin/relebactam, meropenem, murepavadin, tigecycline, and Vabomere.